从和铂医药海外授权,看国内药企创新突破之路

CPHI制药在线
16 Jul

关注并星标CPHI制药在线在全球生物医药产业加速融合的当下,中国制药企业正在向"创新药引领者"的角色蜕变。2025年6月,和铂医药与日本大冢制药达成的6.7亿美元BCMAxCD3双抗授权合作,不仅刷新了国内自免领域License-out金额纪录,更为行业开辟了新的国际化路径。1. 技术平台构筑全球竞争的硬核壁垒和铂医药的Harbour Mice®全人源抗体平台,堪称全球抗体开发领域的"稀缺资产"。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10